Until the introduction of trastuzumab deruxtecan (T-DXd, discussed below in Section 3), the prognostic impact of HER2 expression and the efficacy of targeted therapy was essentially considered tumor specific, not tumor agnostic [6]. Here, ERBB2 is linked to neoplasm.